Fetal Abdominal Subcutaneous Tissue Thickness in Prediction of Fetal Weight in Term Pregnant Women
Launched by ASSIUT UNIVERSITY · Jun 9, 2024
Trial Information
Current as of August 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a method called Fetal Abdominal Subcutaneous Tissue Thickness (FASTT) to see if it can help predict the weight of babies before they are born. The researchers want to find out if measuring the thickness of the fat under the skin of the fetus during a routine ultrasound can indicate whether a baby is larger or smaller than average at birth, especially for women who do not have diabetes.
To participate in this study, women need to be between 37 to 42 weeks pregnant with a single baby and agree to take part. However, those with diabetes, certain pregnancy-related health issues, or specific fetal conditions will not be included. While the trial is not yet recruiting participants, those who join can expect to have their ultrasound measurements taken and contribute to important research that could help improve prenatal care in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Singleton pregnancy.
- • 2. Gestational age between 37-42 weeks.
- • 3. Accepting to be included in the study
- Exclusion Criteria:
- • 1. Pre-gestational diabetes and gestational diabetes.
- • 2. Other medical disorder as hypertensive disorder during pregnancy, cardiac diseases.
- • 3. Congenital fetal malformation affecting birth weight or affecting clavicle.
About Assiut University
Assiut University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that enhance healthcare outcomes. With a strong emphasis on innovation and collaboration, the university engages in a wide array of clinical studies across various disciplines, aiming to contribute valuable insights into disease prevention, diagnosis, and treatment. Assiut University's commitment to ethical research practices and rigorous scientific methodology ensures the integrity and reliability of its clinical trials, ultimately benefiting both the local community and the global medical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported